Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06168071
Other study ID # 202307034
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date November 15, 2023
Est. completion date November 15, 2025

Study information

Verified date December 2023
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about brain waves during transauricular vagus nerve stimulation (taVNS) in healthy children. The main questions it aims to answer are: - What is the safety, tolerability, and physiological response of taVNS in children? - Does the electroencephalogram (EEG) change during taVNS? Participants will - undergo a brief titration session where taVNS will be titrated to below perceptual threshold - receive one session of 30 minutes of taVNS - undergo clinical EEG monitoring during taVNS - Continuous cardiorespiratory monitoring via pulse oximetry and blood pressure every 5 minutes - Answer tolerability questions before, during and after 30 minute taVNS session


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 10
Est. completion date November 15, 2025
Est. primary completion date November 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 7 Years to 18 Years
Eligibility Inclusion Criteria: - Admitted for clinical EEG for spell characterization at investigator's institution Exclusion Criteria: - known history of brain injury - known history of bradycardia - congenital heart disease - pregnant - pacemaker or wearable defibrillator - undergoing active cancer treatment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
taVNS
Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.

Locations

Country Name City State
United States Washington University in St. Louis Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Heart rate Determined by continuous pulse oximeter. If heart rate drops below 60 beats per minute (bpm) in children younger than 9 years and below 50 bpm in children older than 9 years for more than 30 seconds, the stimulation will be stopped. Baseline and continuously for 30 minutes during study visit. It will be recorded and assessed every 5 minutes during 30 minute study visit.
Primary Safety: Oxygen saturation Determined by continuous pulse oximeter. If oxygen saturation drops below 92% for more than 30 seconds, stimulation will stop. Baseline and continuously for 30 minutes during study visit. It will be recorded and assessed every 5 minutes during 30 minute study visit.
Primary Tolerability: Face, Legs, Activity, Cry, Consolability (FLACC) Observation pain assessment before, during and after stimulation. FLACC scale is a 0-10 pain scale with 10 being severe pain and 0 being no pain. Baseline prior to stimulation, 15 minutes into the stimulation and immediately following the 30 minute stimulation.
Primary Tolerability: Tolerance Questionnaire Qualitative survey of side effects, ranking of preference of taVNS activity and 6-point comfort scale (6 being severely uncomfortable). Completed before, during and after stimulation Baseline prior to stimulation, 15 minutes into the stimulation and immediately following the 30 minute stimulation.
See also
  Status Clinical Trial Phase
Terminated NCT01192776 - Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE) N/A
Completed NCT01092637 - The TOBY Children Study N/A
Completed NCT00006516 - Home Stimulation for Brain-Asphyxiated Infants Phase 2
Recruiting NCT05390060 - Delineating Between Pathophysiologic Phenotypes of Hypoxic Ischemic Brain Injury After Cardiac Arrest N/A
Completed NCT02605733 - The Neu-Prem Trial: Neuromonitoring of Preterm Newborn Brain During Birth Resuscitation
Completed NCT00375908 - Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury N/A
Completed NCT00005772 - Whole-Body Cooling for Birth Asphyxia in Term Infants Phase 3
Completed NCT02991976 - Oxygen Concentration and Recovery After Carotid Endarterectomy N/A
Recruiting NCT06081283 - Antiseizure Medication in Seizure Networks at Early Acute Brain Injury Phase 4
Completed NCT03112486 - Out-of-hospital Cardiac Arrest (OHCA) Biomarkers
Completed NCT01793129 - Preemie Hypothermia for Neonatal Encephalopathy N/A
Recruiting NCT04217551 - Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients N/A
Completed NCT04261335 - The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy Phase 1
Not yet recruiting NCT05514665 - Functional Imaging of Baby Brains
Recruiting NCT06048796 - Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest N/A
Completed NCT03543371 - Neuropsychological Outcome After Cardiac Arrest
Not yet recruiting NCT06139250 - Development of a High-speed Multimodal Photoacoustic/Ultrasound System for Functional Imaging of the Neonatal Brain
Recruiting NCT04198792 - Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients
Completed NCT01483495 - Assessing Cerebrovascular Reactivity Based on Cerebral Oximetry: a Pilot Study
Completed NCT03941015 - Tissue Oxygenation During Treatment of Infant Congenital Heart Defects